Structure Therapeutics Inc. American Depositary Shares (GPCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has a cash flow conversion efficiency ratio of -0.089x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-120.11 Million) by net assets ($1.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Structure Therapeutics Inc. American Dep worth for the company's overall valuation and market capitalisation.
Structure Therapeutics Inc. American Depositary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Structure Therapeutics Inc. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their cash flow conversion efficiency. Explore Structure Therapeutics Inc. American Dep cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACC Limited
NSE:ACC
|
-0.111x |
|
Yunnan Shennong Agricultural Industry Group Co Ltd
SHG:605296
|
-0.018x |
|
Stadler Rail AG
SW:SRAIL
|
0.333x |
|
ANSELL (UNSP.ADRS)/4
F:PD1
|
N/A |
|
Shanghai AtHub Co Ltd
SHG:603881
|
0.115x |
|
Beijing Xinleineng Technology Co Ltd
SHE:300593
|
-0.024x |
|
Autohome Inc
NYSE:ATHM
|
0.001x |
|
Jiangsu Lihua Animal Husbandry Co Ltd
SHE:300761
|
0.087x |
Annual Cash Flow Conversion Efficiency for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. View today's stock price for Structure Therapeutics Inc. American Dep for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.52 Billion | $-222.20 Million | -0.147x | -8.65% |
| 2024-12-31 | $864.84 Million | $-116.64 Million | -0.135x | +23.15% |
| 2023-12-31 | $452.97 Million | $-79.49 Million | -0.175x | -143.81% |
| 2022-12-31 | $-115.14 Million | $-46.12 Million | 0.401x | -19.37% |
| 2021-12-31 | $-64.73 Million | $-32.16 Million | 0.497x | -21.85% |
| 2020-12-31 | $-22.47 Million | $-14.28 Million | 0.636x | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more